Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | PTPRA | P18433 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099741 | 1.00 | HDAC6 (0.53) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| SCHEMBL10724996 | 1.00 | HDAC6 (0.53) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| SCHEMBL2058837 | 1.00 | HDAC6 (0.53) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL28366685 | 0.98 | HDAC6 (0.52) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL27539736 | 0.98 | HDAC6 (0.52) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL5906904 | 0.98 | HDAC6 (0.52) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL5570822 | 0.98 | HDAC6 (0.52) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| SCHEMBL10467278 | 0.86 | PTPRA (0.50) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| SCHEMBL1693012 | 0.86 | PTPRA (0.50) | HDAC6HDAC1PTPRAGRIN2DGRIN3B | |
| SCHEMBL22445092 | 0.86 | CYP1A2 (0.47) | HDAC6HDAC1SMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109676-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | RECURSION PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12528779-B2 | Heterocyclic compounds and related methods | RECURSION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240228444-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | RECURSION PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11919868-B2 | Heterocyclic compounds and related methods | RECURSION PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4301746-A1 | DIAZEPINE DERIVATIVES USEFUL IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE | Recursion Pharmaceuticals, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20220380323-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | RECURSION PHARMACEUTICALS, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11345669-B2 | Urea derivatives and methods of use thereof | NodThera Limited (GB) | 2022-05-31 | — | — | US | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200131141-A1 | CHEMICAL COMPOUNDS | NodThera Limited (GB) | 2020-04-30 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109676-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | SLC10A1, SCN1B, HSD3B2 | HDAC6 499/4885HDAC1 1591/4885PTPRA 2226/4885 |
| US-20240228444-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | CYP11B2, CYP11B1, MAPT | HDAC6 165/4885HDAC1 682/4885PTPRA 4011/4885 |
| US-20200131141-A1 | CHEMICAL COMPOUNDS | IL1B, CASP1, IL1A | HDAC6 371/4885HDAC1 414/4885PTPRA 1712/4885 |
| US-12528779-B2 | Heterocyclic compounds and related methods | SLC10A1, SCN1B, NPY5R | HDAC6 784/4885HDAC1 1635/4885PTPRA 2334/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | HDAC6 166/4885HDAC1 1884/4885PTPRA 2405/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | HDAC6 226/4885HDAC1 1875/4885PTPRA 2283/4885 |
| US-11345669-B2 | Urea derivatives and methods of use thereof | IL1B, IL1A, NOD1 | HDAC6 1570/4885HDAC1 761/4885PTPRA 4357/4885 |
| US-20220380323-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | CYP11B2, CYP11B1, MAPT | HDAC6 146/4885HDAC1 1014/4885PTPRA 2572/4885 |
| US-11919868-B2 | Heterocyclic compounds and related methods | CYP11B2, CYP11B1, MAPT | HDAC6 165/4885HDAC1 682/4885PTPRA 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.